Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab Dosing Regimens in Small Cell Lung Cancer (DeLLphi-309)
NCT06745323Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Feb 2025
- Primary completion
- Aug 2029
- Countries
- 16
01
Overview
A Phase 2 trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Started Feb 2025; status: active, not recruiting.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06745323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745323.